{"nctId":"NCT03345979","briefTitle":"A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia","startDateStruct":{"date":"2017-11-15","type":"ACTUAL"},"conditions":["Schizophrenia"],"count":200,"armGroups":[{"label":"Treatment Group 1","type":"EXPERIMENTAL","interventionNames":["Combination Product: Aripiprazole Lauroxil"]},{"label":"Treatment Group 2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Paliperidone Palmitate"]}],"interventions":[{"name":"Aripiprazole Lauroxil","otherNames":["ARISTADA","ARISTADA INITIO"]},{"name":"Paliperidone Palmitate","otherNames":["Invega Sustenna"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has a diagnosis of schizophrenia\n* Requires acute treatment for symptoms of schizophrenia\n* Willing and able to be confined to an inpatient study unit for up to 3-4 weeks\n* Has experienced at least one previous hospitalization for schizophrenia\n* Has been able to achieve outpatient status for more than 3 months in the past year\n* Has a body mass index (BMI) between 18.0 and 40.0 kg/m\\^2\n* Resides in a stable living situation when not hospitalized\n* Has an identified reliable caregiver (for example, family member)\n* Additional criteria may apply\n\nExclusion Criteria:\n\n* Poses a current suicide risk\n* Pregnant, planning to become pregnant, or breastfeeding\n* Initiated first antipsychotic treatment within the past 12 months\n* Has received a long-acting injectable antipsychotic in the past 3 months\n* Has participated in a clinical study involving any investigational product within the past 3 months, or is currently participating in a clinical study involving an investigational product.\n* A positive urine drug test for drugs of abuse\n* Additional criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4","description":"Change within treatment groups of Positive and Negative Syndrome Scale (PANSS) total score between baseline and week 4 based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.4","spread":"11.57"},{"groupId":"OG001","value":"-20.1","spread":"13.72"}]}]}]},{"type":"SECONDARY","title":"Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4","description":"Least squares mean change in Positive and Negative Syndrome Scale (PANSS) between at 4 weeks from Mixed Models Repeated Measures (MMRM). The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.3","spread":"1.28"},{"groupId":"OG001","value":"-19.3","spread":"1.25"}]}]}]},{"type":"SECONDARY","title":"Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9","description":"Change within treatment groups from baseline Positive and Negative Syndrome Scale (PANSS) and 9 weeks based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.8","spread":"11.61"},{"groupId":"OG001","value":"-22.5","spread":"13.98"}]}]}]},{"type":"SECONDARY","title":"Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25","description":"Change within treatment groups at baseline Positive and Negative Syndrome Scale (PANSS) and at 25 weeks based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.3","spread":"11.25"},{"groupId":"OG001","value":"-21.7","spread":"14.37"}]}]}]},{"type":"SECONDARY","title":"Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9","description":"Least squares mean change from baseline Positive and Negative Syndrome Scale (PANSS) and 9 weeks from Mixed Models Repeated Measures (MMRM).The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.8","spread":"1.33"},{"groupId":"OG001","value":"-21.5","spread":"1.34"}]}]}]},{"type":"SECONDARY","title":"Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25","description":"Least squares mean change in Positive and Negative Syndrome Scale (PANSS) total score at week 25 from Mixed Models Repeated Measures. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.0","spread":"1.42"},{"groupId":"OG001","value":"-21.1","spread":"1.53"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious and Non-serious Adverse Events (AEs)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":99},"commonTop":["Injection Site Pain","Weight increased","Akathisia","Headache","Somnolence"]}}}